These compounds attenuate systemic inflammation by lowering circulating levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), biomarkers consistently associated with endothelial dysfunction [124]. The gene discussed is CRP; the disease is endothelial dysfunction.